ArticleFrontiers in endocrinology2026
Serum osteocalcin as a novel biomarker for differentiating growth hormone deficiency from idiopathic short stature.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Analysis of Osteocalcin Hormone Proteoforms with Vitamin D Deficiency in Patients with Diabetes Mellitus Using Multiple-Reaction Monitoring-Mass Spectrometric Immunoassay Approach.Methods and protocols · 2026Article
- Osteocalcin Beyond Bone: Molecular Mechanisms, Endocrine Networks, and Translational Perspectives Across Metabolism, Neurobiology, and Chronic Disease.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The differentiation between Growth Hormone Deficiency (GHD) and Idiopathic Short Stature (ISS) primarily relies on the growth hormone stimulation test (GHST),which is invasive and can cause adverse effects. Objective: To evaluate the diagnostic value of bone turnover markers in distinguishing GHD from ISS. Methods: A cross-sectional study was conducted, enrolling 76 children aged 3-11 years with short stature (37 in the GHD group and 39 in the ISS group). Clinical data including height, weight, bone age, Insulin-like Growth Factor 1(IGF-1), and Peak Growth Hormone (GHP) levels were collected. Eight bone turnover markers were measured: Osteocalcin (OC), β-C-terminal telopeptide of type I collagen (β-CTX), 25-Hydroxyvitamin D (25(OH)D), Vitamin D (VitD), Alkaline Phosphatase (ALP), Parathyroid Hormone (PTH), serum Calcium (Ca), and serum Phosphorus (P). Nonparametric tests were used for intergroup comparisons. Logistic regression and Receiver Operating Characteristic (ROC) curve analyses were performed to assess diagnostic efficacy, and Spearman correlation analysis was employed for correlation evaluation. Results: The OC level in the GHD group was significantly lower than that in the ISS group (P < 0.001), while serum P was higher in the GHD group (P < 0.05). Multivariate analysis identified OC as an independent discriminative factor (OR = 182.585, P < 0.001). ROC curve analysis revealed that OC had an area under the curve (AUC) of 0.949, At a cutoff of 1.026 ng/mL, sensitivity was 86.49% and specificity was 100%. Correlation analysis indicated a positive association between OC levels and GHP (r = 0.6, P < 0.05). Conclusion: Serum OC shows high diagnostic value for distinguishing GHD from ISS, demonstrating significant clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.